Company

Regeneron Pharmaceuticals, Inc.

Headquarters: Tarrytown, NY, United States

Founded: 1988

Employees: 10,368

CEO: Dr. Leonard S. Schleifer M.D., Ph.D.

show_chart NASDAQ: REGN -0.06%

Market Cap

$79.53 Billion

USD as of Jan. 1, 2023

history Market Cap History

Company Description

Regeneron Pharmaceuticals, Inc. is a biotechnology company dedicated to molecules signaling, and targeted antibody drugs. Thanks to its patented treatments and technologies, Regeneron provides remedies for eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic diseases, infectious diseases, and rare diseases.

Regeneron Pharmaceuticals, Inc. market capitalization over time

Evolution of Regeneron Pharmaceuticals, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

history Market Cap History of Regeneron Pharmaceuticals, Inc.

Detailed Description

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Stocks & Indices

Regeneron Pharmaceuticals, Inc. has the following listings and related stock indices.


Stock: NASDAQ: REGN

Stock: BMV: REGN

Stock: Bovespa: REGN34

Stock: FSX: RGO

Key People

Leonard Schleifer (CEO) George Yancopoulos (CSO)

Financials

Revenue: US$8.497 billion (2020)

Net income: US$3.513 billion (2020)


Total assets: US$17.163 billion (2020)

Details

Headquarters:

777 Old Saw Mill River Road

Tarrytown, NY 10591

United States

Phone: 914 847 7000